Inactive Instrument

Entasis Therapeutics Holdings Inc. Stock price

Equities

ETTX

US2936141033

Biotechnology & Medical Research

Dynamic Chart
Entasis Therapeutics Holdings Inc. Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial At IDWEEK 2022 CI
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from S&P TMI Index CI
Innoviva Acquires Remaining Stake in Entasis Therapeutics MT
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from NASDAQ Composite Index CI
Innoviva, Inc. completed the acquisition of the remaining 40% stake in Entasis Therapeutics Holdings Inc. from a group of shareholders. CI
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell 3000E Value Index CI
Entasis Therapeutics Holdings Inc.(NasdaqGM:ETTX) dropped from Russell Microcap Value Index CI
Innoviva to Acquire Remaining Stake in Entasis Therapeutics for $2.20 Per Share in Cash; Entasis Stock Surges Pre-Bell MT
Entasis Therapeutics Holdings Inc. Presents Data Highlights from Phase 3 Attack Trial At 2022 American Thoracic Society Annual Conference CI
Cantor Fitzgerald Downgrades Entasis Therapeutics Holdings to Neutral From Overweight, Adjusts Price Target to $2 From $5 MT
Wedbush Lifts Price Target on Entasis Therapeutics Holdings to $2 From $1.80 on Innoviva's Revised Bid, Maintains Neutral Rating MT
Entasis Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Entasis Therapeutics Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at ECCMID 2022 Conference CI
Top Premarket Decliners MT
Alliance Global Downgrades Entasis Therapeutics Holdings to Neutral From Buy MT
More news
Managers TitleAgeSince
Chief Executive Officer 56 15-04-30
Chief Tech/Sci/R&D Officer 58 15-04-30
Chief Tech/Sci/R&D Officer 63 19-11-03
Members of the board TitleAgeSince
Director/Board Member 62 18-03-31
Director/Board Member 58 17-07-31
Director/Board Member 49 17-07-31
More insiders
Entasis Therapeutics Holdings Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted antibacterial products that address unmet medical needs to treat infections caused by multidrug-resistant pathogens. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), which is an intravenous, combination of sulbactam, an IV b-lactam antibiotic, and durlobactam, a novel broad-spectrum IV b -lactamase inhibitor (BLI) for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. Its second late-stage product candidate is zoliflodacin, which is an orally administered molecule being developed for the treatment of uncomplicated gonorrhea. Its third product candidate is ETX0282CPDP for the oral treatment of urinary tract infections. ETX0282CPDP is a combination of ETX0282, a novel oral BLI, with cefpodoxime proxetil (cefpodoxime), an oral b-lactam antibiotic.
More about the company
  1. Stock
  2. Equities
  3. Stock Entasis Therapeutics Holdings Inc. - Nasdaq